HepatoChem Inc.
Mimicking liver metabolism for drug discovery
This article was originally published in Start Up
Executive Summary
Liver toxicity is the most common safety issue in new drug development. Unfortunately, existing techniques for identifying drug metabolites aren’t that reliable. As a result, drugs frequently enter clinical trials with relatively little or no metabolite data that might alert developers to potential safety problems. HepatoChem Inc. aims to improve matters for its clients with a “chemical liver” designed to mimic the oxidation that can occur during Phase I metabolism.